Evidence map›Paper›PMID 33733316›Full record

ArticleInfectious diseases and therapy2021

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study.

Bo-Huang Liou, Hsin-Yun Sun, Chia-Jui Yang, Ling-Shan Syue, Yu-Lin Lee, Hung-Jen Tang, Hung-Chin Tsai, Chi-Ying Lin, Tun-Chieh Chen, Chun-Yuan Lee and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Bo-Huang LiouDepartment of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan.
Hsin-Yun SunDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Chia-Jui YangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Ling-Shan SyueDepartment of Internal Medicine, National Cheng Kung University Hospital and National Cheng Kung University College of Medicine, Tainan, Taiwan.
Yu-Lin LeeDepartment of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Hung-Jen TangDepartment of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Hung-Chin TsaiSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Chi-Ying LinDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
Tun-Chieh ChenDepartment of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
Chun-Yuan LeeDepartment of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan.
Sung-Hsi HuangDepartment of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
Chia-Wei LiuDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Po-Liang LuDepartment of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan.
Shih-Ping LinDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Ning-Chi WangDepartment of Internal Medicine, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.
Aristine ChengDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Wen-Chien KoDepartment of Internal Medicine, National Cheng Kung University Hospital and National Cheng Kung University College of Medicine, Tainan, Taiwan.
Shu-Hsing ChengDepartment of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan. shcheng@mail.tygh.gov.tw.ORCID http://orcid.org/0000-0002-6256-0527
Chien-Ching HungDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Taiwan HIV Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection.

methodsFrom January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12 weeks off-therapy (SVR12).

resultsOf the 114 patients (mean age, 38.6 years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m

conclusionSimilar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2.

Indexed as

Antiretroviral therapyDirect-acting antiviralsEnd-of-treatment responseEstimated glomerular filtration rateLedipasvirSofosbuvirSustained virologic response

Identifiers

PMID33733316
PMCPMC8116398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.